I have yet to read anything that says Leronlimab is "good science"?!?
In contrast and in reference to a company we both follow, the compound Blarcamesine has had a string of positive FDA trials in multiple indications, with very conservative management. I like that combination much more than no trial evidence and corporate sponsored hype.
Well the same was said about blarcamesine until the recent Rett and PDD results. Making big money in biotech requires a bit of faith on thin evidence, whether LL now or B in 2015 when I loaded the truck. Much prefer to buy in under $2 than at $25.
That is where Management is key. Well run ship keeping cash burn and dilution low is critical. Competence in execution is critical. remaining focused on the objective is critical. CYDY mgt has none of these traits, and I should not have invested in it. Only did to diversify, which is a problem since finding other biotechs with good mgt and good science at less than sky high prices is hard.
Market Data 
Markets 
AI
